Klinický problém hypoglykémie je prítomný v diabetológii už od objavu inzulínu pred viac ako 100 rokmi. Nové technológie v manažmente diabetu, akými sú kontinuálne monitorovanie glukózy (Continuous Glucose Monitoring – CGM) alebo inzulínové pumpy integrované s CGM technológiou do hybridných uzavretých systémov na podávanie inzulínu (Advanced Hybrid Closed Loop Systems – AHCL) majú jednoznačné dôkazy pre signifikantnú a klinicky relevantnú redukciu výskytu hypoglykémie. CGM technológia, okrem samotného efektu na redukciu výskytu hypoglykémie, pomohla v prvom rade odhaliť jej skutočnú a predtým nepoznanú mieru výskytu. Autor v prehľadovom článku diskutuje relevantné klinické štúdie a dáta z reálnej praxe (Real World Evidence – RWE) a ich význam pre klinickú prax.
The clinical problem of hypoglycaemia has been with us since the discovery of insulin more than 100 years ago. Modern diabetes technologies, such as continuous glucose monitoring (CGM) or advanced hybrid closed loop systems (AHCL), have unequivocal evidence for significant and clinically meaningful reduction of hypoglycaemia. On top of that, CGM technology has helped us to discover the real extent of the hypoglycaemia ‘problem’ in the lives of our patients. This article reviews the relevant clinical studies and real world evidence data and their impact on clinical practice.
People living with diabetes have many medical devices available to assist with disease management. A critical aspect that must be considered is how systems for continuous glucose monitoring and insulin pumps communicate with each other and how the data generated by these devices can be downloaded, integrated, presented and used. Not only is interoperability associated with practical challenges, but also devices must adhere to all aspects of regulatory and legal frameworks. Key issues around interoperability in terms of data ownership, privacy and the limitations of interoperability include where the responsibility/liability for device and data interoperability lies and the need for standard data-sharing protocols to allow the seamless integration of data from different sources. There is a need for standardised protocols for the open and transparent handling of data and secure integration of data into electronic health records. Here, we discuss the current status of interoperability in medical devices and data used in diabetes therapy, as well as regulatory and legal issues surrounding both device and data interoperability, focusing on Europe (including the UK) and the USA. We also discuss a potential future landscape in which a clear and transparent framework for interoperability and data handling also fulfils the needs of people living with diabetes and healthcare professionals.
- MeSH
- diabetes mellitus * farmakoterapie MeSH
- elektronické zdravotní záznamy MeSH
- krevní glukóza MeSH
- lidé MeSH
- selfmonitoring glykemie * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Geografické názvy
- Spojené království MeSH
BACKGROUND: Critical care of patients on extracorporeal membrane oxygenation (ECMO) with acute brain injury (ABI) is notable for a lack of high-quality clinical evidence. Here, we offer guidelines for neurological care (neurological monitoring and management) of adults during and after ECMO support. METHODS: These guidelines are based on clinical practice consensus recommendations and scientific statements. We convened an international multidisciplinary consensus panel including 30 clinician-scientists with expertise in ECMO from all chapters of the Extracorporeal Life Support Organization (ELSO). We used a modified Delphi process with three rounds of voting and asked panelists to assess the recommendation levels. RESULTS: We identified five key clinical areas needing guidance: (1) neurological monitoring, (2) post-cannulation early physiological targets and ABI, (3) neurological therapy including medical and surgical intervention, (4) neurological prognostication, and (5) neurological follow-up and outcomes. The consensus produced 30 statements and recommendations regarding key clinical areas. We identified several knowledge gaps to shape future research efforts. CONCLUSIONS: The impact of ABI on morbidity and mortality in ECMO patients is significant. Particularly, early detection and timely intervention are crucial for improving outcomes. These consensus recommendations and scientific statements serve to guide the neurological monitoring and prevention of ABI, and management strategy of ECMO-associated ABI.
- MeSH
- dospělí MeSH
- konsensus MeSH
- lidé MeSH
- mimotělní membránová oxygenace * metody normy MeSH
- monitorování fyziologických funkcí metody MeSH
- péče o pacienty v kritickém stavu normy metody MeSH
- poranění mozku terapie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- směrnice pro lékařskou praxi MeSH
- Klíčová slova
- teplizumab,
- MeSH
- diabetes mellitus 1. typu * diagnóza prevence a kontrola terapie MeSH
- diabetes mellitus MeSH
- glykovaný hemoglobin analýza MeSH
- humanizované monoklonální protilátky terapeutické užití MeSH
- kontinuální monitorování glukózy MeSH
- krevní glukóza MeSH
- lidé MeSH
- regulace glykemie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- přehledy MeSH
Sleep symptoms, including excessive sleepiness, are frequently reported by patients with functional motor disorders (FMD). We aimed to classify the comorbid sleep disorders in FMD, and to investigate the relationship between subjective sleepiness and objective measures of hypersomnia, comparing them with data from people with central hypersomnia. A total of 37 patients (mean [SD] age 46.4 [11.2] years) with clinically definite FMD, and 17 patients (mean [SD] age 41.1 [11.6] years) with central hypersomnia underwent structured medical and sleep history, neurological examination, polysomnography, multiple sleep latency test (MSLT), and questionnaires assessing sleepiness, fatigue, and depression. In all, 23 patients with FMD (62%) reported excessive daytime sleepiness. Evidence of specific sleep disorders was identified in our cohort, with 35% having restless legs syndrome; 49% obstructive sleep apnea; and 8% periodic limb movements in sleep; however, the presence of these disorders was not correlated with subjective sleepiness. Patients with FMD with self-reported sleepiness reported higher fatigue (p = 0.002), depression (p = 0.002), and had longer sleep latencies in the MSLT (p < 0.001) compared to the patients with central hypersomnia. No correlation was found between subjective and objective sleepiness in either group. Fatigue positively correlated with self-reported sleepiness in patients with FMD (p < 0.001). This study did not find objective correlates of increased sleepiness in patients with FMD. While sleep abnormalities were found to be common in FMD, they were not correlated with self-reports of excessive sleepiness. Positive correlations between self-reported sleepiness and fatigue support the current unified model of non-motor symptoms in FMD.
- MeSH
- deprese epidemiologie patofyziologie MeSH
- dospělí MeSH
- komorbidita * MeSH
- lidé středního věku MeSH
- lidé MeSH
- periodické pohyby končetinami ve spánku epidemiologie patofyziologie MeSH
- polysomnografie * MeSH
- poruchy nadměrné spavosti * epidemiologie patofyziologie MeSH
- poruchy spánku a bdění epidemiologie patofyziologie MeSH
- průzkumy a dotazníky MeSH
- somnolence MeSH
- spánková latence fyziologie MeSH
- syndrom neklidných nohou patofyziologie epidemiologie MeSH
- únava patofyziologie epidemiologie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- srovnávací studie MeSH
OBJECTIVE: The objective of this work was to gather an international consensus group to propose a global definition and diagnostic approach of laryngopharyngeal reflux (LPR) to guide primary care and specialist physicians in the management of LPR. METHODS: Forty-eight international experts (otolaryngologists, gastroenterologists, surgeons, and physiologists) were included in a modified Delphi process to revise 48 statements about definition, clinical presentation, and diagnostic approaches to LPR. Three voting rounds determined a consensus statement to be acceptable when 80% of experts agreed with a rating of at least 8/10. Votes were anonymous and the analyses of voting rounds were performed by an independent statistician. RESULTS: After the third round, 79.2% of statements (N = 38/48) were approved. LPR was defined as a disease of the upper aerodigestive tract resulting from the direct and/or indirect effects of gastroduodenal content reflux, inducing morphological and/or neurological changes in the upper aerodigestive tract. LPR is associated with recognized non-specific laryngeal and extra-laryngeal symptoms and signs that can be evaluated with validated patient-reported outcome questionnaires and clinical instruments. The hypopharyngeal-esophageal multichannel intraluminal impedance-pH testing can suggest the diagnosis of LPR when there is >1 acid, weakly acid or nonacid hypopharyngeal reflux event in 24 h. CONCLUSION: A global consensus definition for LPR is presented to improve detection and diagnosis of the disease for otolaryngologists, pulmonologists, gastroenterologists, surgeons, and primary care practitioners. The approved statements are offered to improve collaborative research by adopting common and validated diagnostic approaches to LPR. LEVEL OF EVIDENCE: 5 Laryngoscope, 134:1614-1624, 2024.
- MeSH
- elektrická impedance MeSH
- laryngofaryngeální reflux * diagnóza MeSH
- larynx * MeSH
- lidé MeSH
- monitorování jícnového pH MeSH
- otorinolaryngologové MeSH
- průzkumy a dotazníky MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- MeSH
- antibakteriální látky aplikace a dávkování farmakokinetika škodlivé účinky MeSH
- antifungální látky aplikace a dávkování farmakokinetika škodlivé účinky MeSH
- antivirové látky aplikace a dávkování farmakokinetika škodlivé účinky MeSH
- infekce dýchací soustavy * farmakoterapie MeSH
- lékové interakce MeSH
- lidé MeSH
- mikrobiota účinky léků MeSH
- monitorování léčiv MeSH
- monoklonální protilátky terapeutické užití MeSH
- nežádoucí účinky léčiv klasifikace patologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- přehledy MeSH
